Log in
Register|
jag009 ★★★ NJ, 2015-07-15 18:39 (3993 d 04:50 ago) Posting: # 15088 Views: 9,351 |
|
|
Hi all, Does anyone have experience with raloxifene? If so, what is the intrasubject cv? According to literature it's a HVD (ISCV>=30) but no exact figure. Thanks John Edit: Category changed. [Helmut] |
|
Mauricio Sampaio ★ Brazil, 2015-07-17 02:59 (3991 d 20:31 ago) @ jag009 Posting: # 15098 Views: 7,621 |
|
|
Between 30 - 45%. |
|
d_labes ★★★ Berlin, Germany, 2015-07-17 10:05 (3991 d 13:24 ago) @ Mauricio Sampaio Posting: # 15099 Views: 7,600 |
|
|
Hi John, hi Mauricio, ❝ Between 30 - 45%. Confirmed if CV for Cmax is meant: 1 study pivotal 36 subj. in 2005: CV(Cmax) ~29%; CV(AUC) ~22% 1 study pilot, 12 subj. in 2010: CV(Cmax) ~41%; CV(AUC) ~ 15% — Regards, Detlew |
|
drgunasakaran1 ★★  2015-07-19 18:46 (3989 d 04:43 ago) @ jag009 Posting: # 15105 Views: 7,552 |
|
|
Dear Mr John, ❝ Does anyone have experience with raloxifene? If so, what is the intrasubject cv? According to literature it's a HVD (ISCV>=30) but no exact figure. The literature reported Intrasubject variability of Raloxifene for Cmax was 39.59% as per the bioequivalence study submitted to EMA. Reference: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001075/WC500091423.pdf — Dr Gunasakaran Sambandan MD Disclaimer: The replies/posts are my personal opinions, and they do not represent my company's views on the same. LinkedIn |
|
jag009 ★★★ NJ, 2015-07-20 08:42 (3988 d 14:48 ago) @ drgunasakaran1 Posting: # 15106 Views: 7,431 |
|
|
Thanks everyone. PS Thanks v much for link drgunasakaran1. That is very helpful! John |
Ing. Helmut Schütz